(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Nucor, MSCI, Biogen, and Dow Earnings Due: A Preview

July 23rd, 2023

On Tuesday, July 25, a lineup of notable companies is set to disclose their financial performance for the second quarter of 2023, including: Nucor Corporation (NYSE: NUE), a leading steel producer, will release its earnings before the market opens. Read more

The Week Ahead Earnings: General Electric, Chubb, Sherwin-Williams, and Moody's

July 22nd, 2023

On Tuesday, July 25, a lineup of notable companies is ready to unveil their financial performance, including: General Electric Company (NYSE: GE), a diversified conglomerate, will release its second-quarter 2023 earnings before the stock market op. Read more

Upcoming Earnings: Microsoft, Alphabet, Visa, and Danaher Take the Stage

July 22nd, 2023

On Tuesday, July 25, several prominent companies are scheduled to release their financial results, including: Microsoft Corporation (Nasdaq: MSFT), a global technology leader, will reveal its fiscal-year 2023 fourth-quarter results after the marke. Read more

Gilead Scraps HR-MDS Trial; FDA OKs Verrica's Molluscum Treatment

July 22nd, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) announced the termination of the Phase 3 ENHANCE study evaluating magrolimab plus azacitidine as a first-line treatment for higher-risk myelodysplastic syndromes (HR-MDS) due to futility based on a planned analysi. Read more

Boeing Secures $393M+ Contract Modification; Key Upcoming Date for F5 and Ryanair

July 22nd, 2023

The Boeing Company (NYSE: BA) was awarded a substantial contract modification worth $393,091,720 for Apache AH-64E aircraft, alongside support services and equipment.  The Army Contracting Command at Redstone Arsenal, Alabama, is responsible . Read more

Breaking: Booz Allen Hamilton Settles Civil Case for $377.5M

July 22nd, 2023

According to a regulatory filing with the SEC, Booz Allen Hamilton Holding Corporation (NYSE: BAH) has reached a significant settlement agreement with the U.S. Department of Justice (DOJ) and on behalf of the Defense Contract Management Agency to res. Read more

Mirati Therapeutics' KRAZATI Faces Setback; Comerica Q2 Earnings Beat

July 21st, 2023

Mirati Therapeutics, Inc. (Nasdaq: MRTX) faced a setback when the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for its dr. Read more

SEC Settlement Propels DWAC; Regions Financial Q2 Earnings Meet Estimates

July 21st, 2023

Shares of Digital World Acquisition Corp. (Nasdaq: DWAC) surged more than 15% after settling fraud charges with the SEC. The charges were related to material misrepresentations made in forms filed during DWAC's initial public offering and its planned. Read more

Evertec Reveals Upbeat Outlook; Hewlett Packard Secures $26.48M Contract

July 21st, 2023

Evertec, Inc. (NYSE: EVTC) and Sinqia have entered a definitive agreement for Evertec's acquisition of Sinqia, a prominent player in Brazil's financial services software market. The deal is set at a value of R$27.19 per share, with a potential daily . Read more

Breaking: Evelo Biosciences and Bio-Rad Agree on Sublease Termination and Surrender Deal

July 20th, 2023

According to a regulatory filing with the SEC, Evelo Biosciences, Inc. (Nasdaq: EVLO) has entered into a Sublease Termination and Surrender Agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO). The agreement terminates the Sublease, which provided E. Read more